当前位置: 首页 > 期刊 > 《中国医药科学》 > 2014年第21期
编号:13123049
利尿剂在抗心衰治疗中的地位(3)
http://www.100md.com 2014年11月1日 《中国医药科学》 2014年第21期
     [14] Asare K.Management ofLoop Diuretic Resistance in the IntensiveCare Unit[J]. Am J Health Syst Pharm,2009,66: 1635-1640.

    [15] Chow KM,Szeto CC,Wong TY,et al.Risk factors for thiazide-induced hypona traemia[J]. QJM,2003, 96 (12):911-917.

    [16] Sica DA.Diuretic- related side effects: development and treatment[J] . J Clin Hypertens(Greenw ich), 2004,6 (9):532-540.

    [17] Goldsmith SR,Gheorghiade M.Vasopress in antagonism in heart failure[J].J Am Coll Cardio,2005,46(10):1785-1791.

    [18] Hawkins RG,Houston MC.Is population- w ide diuretic use directly associated with the incidence of end-stagerenal disease in the United States A hypothesis[J].Am J Hypertens,2005,18(6):744-749.

    [19] Akram M,Reddan D.Diuretic use and ESRD,precipitating factor or epiphenomenon[J].Am J Hypertens,2005,18(6):739-740.

    [20] Paterna S,Parrinello G,Cannizzaro S,et al. Medium term effects of different dosage of diuretic, sodium,and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure[J].Am J Cardiol,2009,103(1):93-102.

    (收稿日期:2014-08-21), 百拇医药(姚舜杰?朱宗华)
上一页1 2 3